Investigational drug · Phase 2
RO7198457
Also called: Autogene Cevumeran
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Colorectal Cancer Stage II, Colorectal Cancer Stage III, Adenocarcinoma, Pancreatic Ductal.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
3 still active
All registered trials
6
Any phase or sponsor naming "RO7198457"
First trial start
2018
Dec 21, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RO7198457", any sponsor or status.
Conditions studied
As listed on its trial records.
- Colorectal Cancer Stage II
- Colorectal Cancer Stage III
- Adenocarcinoma, Pancreatic Ductal
- Muscle-invasive Urothelial Carcinoma
- Advanced Melanoma
Approved drugs for the same conditions: Colorectal cancer · Melanoma · Pancreatic cancer · Bladder and urothelial cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "RO7198457" as an intervention, largest first.
- A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal CancerPivotal-lookingActive, not recruiting
BioNTech SEIndustry
NCT04486378 · 327 participants (planned) · Start Mar 8, 2021 · Primary completion Nov 2026
Drug: RO7198457 intravenous (IV) · For: Colorectal Cancer Stage II; Colorectal Cancer Stage III
Sites: Greenbrae, California; Indianapolis, Indiana; Minneapolis, Minnesota · 85 sites in all
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT03289962 · 273 participants · Start Dec 21, 2017 · Primary completion Jul 1, 2025
Drug: Autogene cevumeran; Atezolizumab · For: Melanoma; Non-Small Cell Lung Cancer; Bladder Cancer and 5 more
Sites: Scottsdale, Arizona; Los Angeles, California; San Francisco, California · 33 sites in all
- A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.Pivotal-lookingCompleted
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT03815058 · 131 participants · Start Dec 21, 2018 · Primary completion Jan 21, 2025
Drug: Autogene cevumeran; Pembrolizumab · For: Advanced Melanoma
Sites: Duarte, California; La Jolla, California; San Francisco, California · 41 sites in all
- A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)Active, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06534983 · 62 participants (planned) · Start Dec 9, 2024 · Primary completion Nov 10, 2027
Drug: Autogene Cevumeran; Nivolumab · For: Muscle-invasive Urothelial Carcinoma
Sites: Basking Ridge, New Jersey; Middletown, New Jersey; Montvale, New Jersey · 38 sites in all
- Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With SurgeryActive, not recruiting
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT04161755 · 29 participants · Start Dec 13, 2019 · Primary completion Nov 11, 2026
Drug: Atezolizumab; RO7198457 and 1 more · For: Pancreatic Cancer
Sites: Basking Ridge, New Jersey; Middletown, New Jersey; Montvale, New Jersey · 7 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04267237 · 0 participants · Start Mar 31, 2021 · Primary completion Sep 30, 2025
Drug: Atezolizumab; RO7198457 · For: Non-small Cell Lung Cancer (NSCLC)
Newest research
PubMed records naming it or its code names, newest first.
- Messenger RNA vaccine platforms from molecular optimization to infectious disease and cancer immunotherapy: a narrative review.
Wang Q, Sun Z, Liu H · Transl Cancer Res 2026
- Personalized neoantigen mRNA vaccines for pancreatic cancer: the role of lipid nanoparticle delivery systems.
Debnath D · Daru 2026
- Personalized mRNA Neoantigen Vaccines in Cancer: Linking Precision Antigen Selection, Immune Remodeling, and Checkpoint Blockade.
Demircan T, Yldrm B, Ünsal H, et al. · Int J Mol Sci 2026
- Personalized cancer vaccines: bridging immune-oncology and precision medicine for advanced therapeutics.
Ye L, Zhao G, Ma J, et al. · Signal Transduct Target Ther 2026
- Cancer vaccines: comprehensive review.
Clifford RE, Manu N, Yang Q, et al. · BJS Open 2026
- mRNA vaccines in oncology: personalized cancer immunization and neoantigen targeting.
Parganiha M, Rathored J, Sai Painkra D · Mol Cell Oncol 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.